Drugs / MDX447
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005813 | Mar 1997 → Jan 2003 | central nervous system neoplasm | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX447 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005813 ↗ |
| Known as | EMD-82633 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109391 ↗ |
| Route | Other | “intratumoral bispecific antibody MDX447” NCT00005813 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 cross-linking agent” CHEMBL2109391 ↗ |
| Target | FCGR1A | “High affinity immunoglobulin gamma Fc receptor I cross-linking agent” CHEMBL2109391 ↗ |